WASHINGTON, December 24, 2025: The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s Wegovy oral pill for chronic weight management, marking the first time an oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist has been authorized for long-term obesity treatment in adults. The once-daily tablet, containing 25 milligrams of semaglutide, expands Novo Nordisk’s portfolio of metabolic therapies that includes the injectable versions of Wegovy and the diabetes medications Ozempic and Rybelsus. The approval is based on clinical data demonstrating that the oral form of semaglutide provides significant weight reduction comparable to injectable treatments. In the OASIS 4 phase 3 trial, adults with obesity or overweight who took the Wegovy pill in combination with a reduced-calorie diet and increased physical activity achieved an average weight loss of approximately 16.6 percent from baseline, compared with minimal weight change in participants who received a placebo.
Safety and tolerability findings were consistent with previous studies of semaglutide, with gastrointestinal symptoms reported as the most common side effects. The newly approved medication is indicated not only for chronic weight management but also to reduce the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death in adults who have overweight or obesity along with established cardiovascular disease. The FDA decision follows growing evidence linking semaglutide-based therapies to improved cardiometabolic outcomes in patients with obesity-related health risks. Novo Nordisk said the Wegovy pill will be available in the United States beginning in early January 2026. Manufacturing has already commenced at the company’s U.S. production facilities to ensure supply continuity. The Danish pharmaceutical company has also submitted regulatory filings in several other markets, including the European Union, as part of a global rollout strategy.
Novo Nordisk secures approval for Wegovy weight loss pill
The approval comes amid heightened global demand for anti-obesity medications. Over the past two years, GLP-1 receptor agonists have emerged as one of the fastest-growing therapeutic categories in pharmaceuticals, driven by strong efficacy data and increasing recognition of obesity as a chronic disease requiring medical treatment. Wegovy, in its injectable form, became one of the world’s best-selling drugs in 2024, with demand often outpacing supply. Industry analysts have noted that the addition of an oral option could broaden accessibility for patients who prefer pills over injections. The convenience of a once-daily tablet may help expand adoption among individuals hesitant to use injectable therapies. Competitors are expected to follow closely, with companies such as Eli Lilly developing oral formulations of their own GLP-1-based weight loss medications.
Novo Nordisk stated that the U.S. list price for the Wegovy pill will start at approximately 149 dollars per month for the initial dosing period, with patient savings programs to improve affordability. Coverage discussions with major insurers are ongoing, as payers assess inclusion of obesity medications under medical and pharmacy benefits. Despite increasing availability, access to GLP-1 therapies continues to vary across health plans and employer coverage networks. Clinical experts have described the FDA’s decision as a major milestone in obesity treatment, emphasizing that an effective oral option represents a significant advancement for patients. Medical organizations continue to recommend that pharmacologic therapy be combined with lifestyle modification, including dietary and physical activity changes, to achieve and maintain healthy weight outcomes.
Novo Nordisk begins production at U.S. facilities
The approval of the Wegovy pill further reinforces the expanding role of GLP-1 receptor agonists in managing obesity and related cardiometabolic disorders. Obesity affects more than 100 million adults in the United States, according to the Centers for Disease Control and Prevention, and is associated with increased risk of diabetes, cardiovascular disease, and certain cancers. By offering a new oral therapeutic option, the FDA decision broadens the clinical toolkit available to physicians treating this chronic condition. Novo Nordisk’s announcement caps a landmark year for the company, which has seen rapid growth in its obesity and diabetes care segment. The introduction of the Wegovy pill underscores continued innovation in metabolic medicine and positions the therapy as a potentially transformative option for millions of adults seeking effective, non-injectable weight management treatments. – By Content Syndication Services.